PARP Inhibitors in Patients With Newly Diagnosed Advanced Ovarian Cancer: A Meta-Analysis of Randomized Clinical Trials

Background: The efficacy of poly(adenosine diphosphate–ribose) polymerase inhibitors (PARPi) as a maintenance therapy in patients with newly diagnosed advanced ovarian cancer remains unclear. We conducted a meta-analysis to assess the benefits and safety of PARPi maintenance therapy in patients with...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yizi, Ren, Fang, Song, Zixuan, Wang, Xiaoying, Zhang, Chiyuan, Ouyang, Ling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7417336/
https://www.ncbi.nlm.nih.gov/pubmed/32850351
http://dx.doi.org/10.3389/fonc.2020.01204

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7417336/
https://www.ncbi.nlm.nih.gov/pubmed/32850351
http://dx.doi.org/10.3389/fonc.2020.01204

Ejemplares similares